Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Fineline Cube Aug 11, 2026
Company Deals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Fineline Cube Aug 11, 2026
Company Deals

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

Fineline Cube Aug 11, 2026
Company Deals

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

Fineline Cube Aug 11, 2026
Company Deals

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

Fineline Cube Aug 11, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Fineline Cube Aug 11, 2026
Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Fineline Cube Aug 11, 2026
Company Drug

Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome

Fineline Cube Jan 17, 2024

Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...

Company Deals

SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China

Fineline Cube Jan 17, 2024

SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...

Company Deals

Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution

Fineline Cube Jan 17, 2024

Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...

Company Deals

XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China

Fineline Cube Jan 17, 2024

Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...

Company Drug

InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248

Fineline Cube Jan 17, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...

Company Drug

Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001

Fineline Cube Jan 17, 2024

China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...

Company Deals

Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions

Fineline Cube Jan 16, 2024

Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in...

Company Drug

3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors

Fineline Cube Jan 16, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...

Company Drug

Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment

Fineline Cube Jan 16, 2024

Hope Medicine Inc., based in China, has announced the first patient dosing in a global...

Company Drug

Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China

Fineline Cube Jan 16, 2024

Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...

Company

AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit

Fineline Cube Jan 16, 2024

AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...

Company Drug

SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer

Fineline Cube Jan 16, 2024

SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Company Deals

China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million

Fineline Cube Jan 16, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Drug

Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure

Fineline Cube Jan 16, 2024

Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...

Company Drug

CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine

Fineline Cube Jan 16, 2024

CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...

Company Deals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

Fineline Cube Jan 16, 2024

Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...

Company Deals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

Fineline Cube Jan 16, 2024

Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...

Company Drug

RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 16, 2024

China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...

Company Drug

CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors

Fineline Cube Jan 16, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...

Posts pagination

1 … 455 456 457 … 706

Recent updates

  • Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets
  • Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector
  • Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps
  • Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy
  • CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Company Deals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.